Similarly, BRCA-mutant cells rely on POLζ for gap filling and viability and, as such, JH-RE-06, a small molecule inhibitor of REV1-POLζ, reduced in vitro and in vivo growth of BRCA-mutant cancer cells [36]. This evidence concerns the gene REV3L and cancer.